Cargando…

Tumor senescence leads to poor survival and therapeutic resistance in human breast cancer

BACKGROUND: Breast cancer (BRCA) is the most common malignant tumor that seriously threatens the health of women worldwide. Senescence has been suggested as a pivotal player in the onset and progression of tumors as well as the process of treatment resistance. However, the role of senescence in BRCA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhai, Jingtong, Han, Jiashu, Li, Cong, Lv, Dan, Ma, Fei, Xu, Binghe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019818/ https://www.ncbi.nlm.nih.gov/pubmed/36937388 http://dx.doi.org/10.3389/fonc.2023.1097513

Ejemplares similares

High SURF4 expression is associated with poor prognosis of breast cancer
por: Zhai, Jingtong, et al.
Publicado: (2022)

Microglia-Specific Expression of HEXA and HEXB Leads to Poor Prognosis in Glioblastoma Patients
por: Jia, Mengxian, et al.
Publicado: (2021)

Prognostic Factors and a Model for Occult Breast Cancer: A Population-Based Cohort Study
por: Zhang, Di, et al.
Publicado: (2022)

A Novel Prognostic Nomogram for Predicting Survival of Hormone Receptor-Positive and HER2 Negative Advanced Breast Cancer Among the Han-Population
por: Zhu, Yimin, et al.
Publicado: (2022)

Palbociclib Induces Senescence in Melanoma and Breast Cancer Cells and Leads to Additive Growth Arrest in Combination With Irradiation
por: Jost, Tina, et al.
Publicado: (2021)

EYA2 Correlates With Clinico-Pathological Features of Breast Cancer, Promotes Tumor Proliferation, and Predicts Poor Survival
por: Xu, Hanxiao, et al.
Publicado: (2019)

SIPL1, Regulated by MAZ, Promotes Tumor Progression and Predicts Poor Survival in Human Triple-Negative Breast Cancer
por: He, Juanjuan, et al.
Publicado: (2021)

Chemotherapy Decision-Making and Survival Outcomes in Older Women With Early Triple-Negative Breast Cancer: Evidence From Real-World Practice
por: Xiu, Meng, et al.
Publicado: (2022)

Overexpression of GINS4 Is Associated With Tumor Progression and Poor Survival in Hepatocellular Carcinoma
por: Zhang, Ziying, et al.
Publicado: (2021)

Risk Factors and Survival of Patients With Liver Metastases at Initial Metastatic Breast Cancer Diagnosis in Han Population
por: Lin, Shaoyan, et al.
Publicado: (2021)

Relationship between metabolic reprogramming and drug resistance in breast cancer
por: Lv, Linlin, et al.
Publicado: (2022)

Breast Cancer in Chinese Females Aged 25 Years and Younger
por: Li, Lixi, et al.
Publicado: (2021)

Editorial: Induced cell senescence as a therapeutic strategy for cancer treatment
por: He, Kaiyue, et al.
Publicado: (2022)

Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer
por: Guan, Xiuwen, et al.
Publicado: (2021)

Serum sodium ions and chloride ions associated with taxane-induced peripheral neuropathy in Chinese patients with early-stage breast cancer: A nation-wide multicenter study
por: Zhai, Jingtong, et al.
Publicado: (2022)

Overcoming the therapeutic resistance of hepatomas by targeting the tumor microenvironment
por: Zhang, Jiaxin, et al.
Publicado: (2022)

Sex-Based Heterogeneity in the Clinicopathological Characteristics and Prognosis of Breast Cancer: A Population-Based Analysis
por: Han, Yiqun, et al.
Publicado: (2021)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

ESR1 fusions and therapeutic resistance in metastatic breast cancer
por: Nagy, Zsuzsanna, et al.
Publicado: (2023)

Editorial: The molecular mechanisms of metastasis and therapeutic resistance in breast cancer
por: Liang, Yuanke, et al.
Publicado: (2023)

Immune Checkpoint FGL1 Expression of Circulating Tumor Cells Is Associated With Poor Survival in Curatively Resected Hepatocellular Carcinoma
por: Yan, Qing, et al.
Publicado: (2022)

The Dual Role of Cellular Senescence in Developing Tumors and Their Response to Cancer Therapy
por: Schosserer, Markus, et al.
Publicado: (2017)

A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer
por: Hu, Nanlin, et al.
Publicado: (2021)

Corrigendum: ESR1 fusions and therapeutic resistance in metastatic breast cancer
por: Nagy, Zsuzsanna, et al.
Publicado: (2023)

Primary Tumor Surgery for Patients with De Novo Stage IV Breast Cancer can Decrease Local Symptoms and Improve Quality of Life
por: Si, Yiran, et al.
Publicado: (2020)

“High-Risk Breast Cancer Screening in BRCA1/2 Carriers Leads to Early Detection and Improved Survival After a Breast Cancer Diagnosis”
por: Shraga, Shay, et al.
Publicado: (2021)

Extracellular matrix-derived mechanical force governs breast cancer cell stemness and quiescence transition through integrin-DDR signaling
por: Li, Cong, et al.
Publicado: (2023)

Editorial: The role of tumor microenvironment in primary liver cancer therapeutic resistance
por: Pu, Zhangya, et al.
Publicado: (2022)

Distinct Tumor Microenvironment at Tumor Edge as a Result of Astrocyte Activation Is Associated With Therapeutic Resistance for Brain Tumor
por: Lin, Chiu-Min, et al.
Publicado: (2019)

Prognosis signature for predicting the survival and immunotherapy response in esophageal carcinoma based on cellular senescence-related genes
por: Wang, Yue, et al.
Publicado: (2023)

Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)

Upregulated FADD is associated with poor prognosis, immune exhaustion, tumor malignancy, and immunotherapy resistance in patients with lung adenocarcinoma
por: He, Miao, et al.
Publicado: (2023)

Localization of GPSM2 in the Nucleus of Invasive Breast Cancer Cells Indicates a Poor Prognosis
por: Deng, Mingming, et al.
Publicado: (2020)

Hepatocellular Senescence: Immunosurveillance and Future Senescence-Induced Therapy in Hepatocellular Carcinoma
por: Liu, Peng, et al.
Publicado: (2020)

Senescence-Induced Chemoresistance in Triple Negative Breast Cancer and Evolution-Based Treatment Strategies
por: Chakrabarty, Anindita, et al.
Publicado: (2021)

Molecular Interplays Between Cell Invasion and Radioresistance That Lead to Poor Prognosis in Head-Neck Cancer
por: You, Guo-Rung, et al.
Publicado: (2021)

FOXD1 is associated with poor outcome and maintains tumor-promoting enhancer–gene programs in basal-like breast cancer
por: Kumegawa, Kohei, et al.
Publicado: (2023)

Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage
por: Guan, Xiuwen, et al.
Publicado: (2020)

COL5A1 Serves as a Biomarker of Tumor Progression and Poor Prognosis and May Be a Potential Therapeutic Target in Gliomas
por: Gu, Sujie, et al.
Publicado: (2021)

PML, SUMOylation, and Senescence
por: Ivanschitz, Lisa, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_jbj0dn4ip8kq19tqkn3vh0l2ti